Latest Conference Coverage

Findings from a late-breaking poster presented at CMSC 2025 suggest that CBT does not improve fatigue severity or impact in patients with multiple sclerosis.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]

New long-term data reveals ponesimod's effectiveness in reducing relapses and MRI lesions in relapsing multiple sclerosis patients, ensuring safety over 8.2 years.

Neurologists advocate for personalized treatment approaches in older MS patients, emphasizing the importance of individual assessment over age-based rules for DMT discontinuation.

The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]

Fenebrutinib shows promising results in reducing relapse rates and disability progression in relapsing multiple sclerosis patients over two years.

The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]

A recent study reveals that patients on ofatumumab experience fewer worsening MS symptoms compared to those on ocrelizumab, enhancing treatment stability.

Cladribine shows promising results in reducing relapse rates for patients with relapsing multiple sclerosis after inadequate response to injectable therapies.

Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.

The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]

A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients compared to anti-CD20 treatments.

Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

A new survey presented at CMSC 2025 highlighted the prevalence of burnout and job-related stress among neurology-based advanced practice providers and clinical pharmacists in the United States.

New findings reveal ozanimod shows no significant rebound effect in relapsing MS patients after treatment discontinuation, ensuring safer transitions.

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.